Iodine-131
Intended use
Diagnosis and treatment of the Thyroid Gland: for assessing the functional state of the thyroid gland, performing thyroid gland scans and scintigraphy for various conditions, including diagnosing thyroid dysfunction, as well as well-differentiated thyroid cancer and metastases. For therapeutic purposes, the medication is used in treating hyperthyroidism and metastases of thyroid cancer.
Grade:
1. Non-carrier added radionuclide;
2. GMP product;
3. Tested for sterility and bacterial endotoxins.
Chemical form: 131I in 0.1M NaOH solution | 131I, carrier free, in 0.05M NaOH solution containing 0.001M Na2S2O3
Appearance: transparent, colourless liquid
Half-life period: 8.02 days
Radiochemical purity, %: ≥ 95 | ≥ 98
Radioactive concentration, mCi/ml: ≥ 2000.0
Specific activity, Ci/mg: > 6.5
Diagnosis and treatment of the Thyroid Gland: for assessing the functional state of the thyroid gland, performing thyroid gland scans and scintigraphy for various conditions, including diagnosing thyroid dysfunction, as well as well-differentiated thyroid cancer and metastases. For therapeutic purposes, the medication is used in treating hyperthyroidism and metastases of thyroid cancer.
Grade:
1. Non-carrier added radionuclide;
2. GMP product;
3. Tested for sterility and bacterial endotoxins.
Chemical form: 131I in 0.1M NaOH solution | 131I, carrier free, in 0.05M NaOH solution containing 0.001M Na2S2O3
Appearance: transparent, colourless liquid
Half-life period: 8.02 days
Radiochemical purity, %: ≥ 95 | ≥ 98
Radioactive concentration, mCi/ml: ≥ 2000.0
Specific activity, Ci/mg: > 6.5
Other products
